Selvita Reports First Quarter 2019 Financial Results and Provides Corporate Update

Wednesday, May 22, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- Investigational New Drug (IND) application to conduct a Phase 1 study of selective CDK8 inhibitor SEL120 cleared by U.S. Food and Drug Administration (FDA)

SELVITA CRO

Consolidated Statements of Operations

 (In thousands)

Three Months EndedMarch 31,

2019

2018

External revenue

4,580

3,601

Internal revenue

145

225

Grant revenue

231

191

Total revenue

4,956

4,016

Operating expenses

4,448

3,443

EBIT

508

574

EBITDA (with IFRS16 impact -> only Q1 2019)

1,170

848

EBITDA (IFRS16 impact excluded)

944

848



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store